Scientific Workshop on HIV Vaccine and Microbicide Research

Bundesinstitut f ōr Arzneimittel
und Medizinprodukte
Draft Programme
Scientific Workshop on HIV Vaccine and Microbicide Research
Organized by The Robert Koch Institut (RKI), Paul-Ehrlich-Institut (PEI), Bundesinstitut für
Arzneimittel und Medizinprodukte (BfArM), International AIDS Vaccine Initiative
(IAVI)
Place:
Berlin
Date:
30 June and 1 July 2009
Tuesday, 30 June 2009
10.00 - 11.00
Registration of participants
11.00 - 11.10
Welcome, Prof. Dr. Drs. h.c. Jörg Hacker, Robert Koch Institut
11.10 – 11.30
Welcome address and introduction of the programme, and objective of
the workshop, Prof. Dr. Reinhard Kurth, Robert Koch Fellow, Robert Koch
Institut
Chair: Frans van den Boom
11.30 - 12.15
Status of microbicide R&D: challenges and priorities part 1,
Prof. Dr. Robin Shattock, St. George’s University of London
12.15 - 12.45
Status of microbicide R&D: challenges and priorities part 2,
Dr. Thomas Mertenskoetter, International Partnership for Microbicides
12.45 - 14.00
Lunch buffet
14.00 - 14.30
Testing microbicides in non-human primates, Dr. Christiane Stahl-Hennig,
Deutsches Primatenzentrum GmbH
14.30 - 15.00
Induced Suicide of HIV, Prof. Dr. Karin Mölling, University of Zurich,
Institute of Advanced Studies, Berlin
15.00 – 16.00
Status of global AIDS vaccine R&D and IAVI’s R&D programme
Dr. Wayne Koff, International AIDS Vaccine Initiative
16.00 - 16.30
Coffee break
Page | 1
16.30 - 17.30
Panel discussion
Panelists will discuss lessons learned from microbicide and vaccine
research in working towards mucosal immunity, and will identify a set of
R&D priorities.
Moderator:
Prof. Dr. Robin Shattock, St. George’s University of London
Panelists:
Dr. Christiane Stahl-Hennig, Deutsches Primatenzentrum GmbH
Dr. Wayne Koff, International AIDS Vaccine Initiative
Prof. Dr. Reinhard Kurth, Robert Koch Fellow, Robert Koch Institut
Dr. Thomas Mertenskoetter, International Partnership for Microbicides
Dr. Arne Skerra, University of Munich
17.30 - 18.30
T-cell immunity, Prof. Dr. Sarah Rowland-Jones, MRC Human
Immunology Unit, Oxford University
19.00
Networking dinner
Wednesday, 1 July 2009
Chair: Prof. Dr. Robin Shattock
09.00 – 10.00
Neutralizing antibodies, Prof. Dr. Dennis Burton, The Scripps Research
Institute
10.00 – 11.00
AIDS vaccine R&D in Germany – Part 1
Moderator:
Prof. Dr. Jürgen Rockstroh, University of Bonn
Speakers:
10.00 – 10.15
Differential regulation of humoral immune responses to Gag and Env
proteins, Prof. Dr. Klaus Überla, University Bochum
10.15 – 10.30
From concepts to trials and then? - A European-Chinese experience,
Prof. Dr. Hans Wolf, University Regensburg
10.30 – 10.45
AIDS vaccine studies in the SIV/non-human primate model: A personal
perspective, Dr. Steven Norley, Robert Koch Institut
10.45 – 11.00
A novel vaccination approach through direct targeting of cross-presenting
CD8+ DC in vivo, Prof. Dr. Richard Kroczek, Robert Koch Institut
Page | 2
11.00 - 11.30
Coffee break
11.30 - 13.00
AIDS vaccine R&D in Germany – Part 2
Moderator:
Prof. Dr. Jürgen Rockstroh, University of Bonn
Speakers:
11.30 – 11.45
What can we learn from therapeutic HIV vaccines for prevention,
Dr. Jan van Lunzen, University Hamburg
11.45 – 12.00
Designing HIV Candidate vaccines: Iterative process from clinic to bench,
Prof. Dr. Ralf Wagner, University Regensburg
12.00 – 12.15
MVACTOR: Characterization and optimization of vaccinia virus MVA as a
vaccine against AIDS, Prof. Dr. Gerd Sutter, University of Munich
12.15 – 12.30
HIV vaccine – lessons learned from other retroviruses, Dr. Joachim
Denner, Robert Koch Institut
12.30 – 12.45
Utilization of foamy viruses for vaccine antigen expression and
presentation, Prof. Martin Löchelt, Deutsches Krebsforschungs-zentrum
12.45 – 13.00
Strategies for the development of T-cell based HIV-1 vaccines, Prof. Dr.
Thomas Harrer, University of Erlangen-Nuremberg
13.00 - 14.00
Lunch buffet
Successive roundtables
14.00 - 14.30 Session one: Neutralizing antibodies and B-cell immunology: facilitated by
Prof. Dr. Dennis Burton, The Scripps Research Institute
Whilst there currently is significant focus in AIDS vaccine R&D on cell-mediated immune
responses, and more recently also on neutralizing antibodies, there is relatively little
investigation on the role of B cells in achieving immune responses able to protect against HIV
infection. An improved understanding of B-cell biology, including the interaction with CD4+ T
cells and antigen presenting cells, will be critical to improve manipulation of antibody responses.
This session will review important gaps in our understanding of the role of B cells in generating
immunity, and proposals on how to address those gaps. This session will also focus on the
selection of antigen able to induce neutralizing antibodies and on the experience with successful
vaccines inducing neutralizing antibodies.
Page | 3
14.30 - 15.00 Session two: Antigen design and T-cell immunology: facilitated by Prof. Dr.
Sarah Rowland-Jones, MRC Human Immunology Unit, Oxford University
AIDS vaccine R&D is investing increasingly in vector design, yet there is insufficient focus on
antigen design (identification and systematic analysis of the best combination of antigens). Of
particular importance is the identification of relevant antigens and T-cell epitopes in elite
controllers, and the antigens that correlate with control of SIV in the live-attenuated model. In
addition, systematic testing of antigens in preclinical and clinical research is required, with the
aim to optimize the T-cell mediated immune responses. This session will review important gaps
in efforts to optimize antigen design, and proposals on how to address those gaps.
15.00 - 15.30 Session three: Vaccine design to induce both neutralizing antibodies and an
effective T-cell response: facilitated by Dr. Wayne Koff, International AIDS Vaccine Initiative
15.30 - 16.30
Panel discussion
What are the R&D opportunities for Germany’s research programmes
based on the recommendations from the roundtable discussions, and how
do these programmes link to and support international R&D efforts. Prior
to the panel discussion, facilitators of roundtables of day one and two will
present key findings and recommendations
Moderator:
Prof. Dr. Klaus Cichutek, Paul-Ehrlich-Institut
Panelists:
Prof. Dr. Dennis Burton, The Scripps Research Institute
Dr. Joachim Denner, Robert Koch Institut
Dr. Wayne Koff, International AIDS Vaccine Initiative
Prof. Dr. Jürgen Rockstroh, University of Bonn,
Prof. Dr. Sarah Rowland-Jones, Oxford University
Prof. Dr. Ralph Wagner, University Regensburg
Prof. Dr. Hans Wolf, University Regensburg
16.30 - 17.00
Wrap up and conclusion by Prof. Dr. Reinhard Kurth, Robert Koch Fellow,
Robert Koch Institut
Page | 4